Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:39 PM
Ignite Modification Date:
2025-12-24 @ 9:39 PM
NCT ID:
NCT00672932
Eligibility Criteria:
Inclusion Criteria:
* Capacity to provide informed consent.
* Documented HIV-1 infection.
* History of continuous cART treatment (with at least three drugs) for at least 2 years.
* Documentation of 'undetectable' plasma HIV-1 RNA for at least 1 year.
* HIV-1 RNA \<50 copies/mL in plasma and CSF at screening visit.
Exclusion Criteria:
* Contraindication to LP (suspicion of CNS mass lesion, bleeding diathesis, etc.).
* Prior experience with raltegravir or contraindication to raltegravir treatment, including medication interactions that might compromise ongoing antiretroviral therapy or treatment of other conditions.
* Active opportunistic infections or neurological diseases.
* Other conditions or treatments likely to interfere with treatment or evaluation.
* Hemoglobin \< 10 Gm/dL.
* Pregnant or anticipating pregnancy during study.
* Active substance abuse.
* Subjects taking rifampin, phenytoin, Phenobarbital or other drugs that accelerate raltegravir metabolism and might decrease its tissue concentrations.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00672932
Study Brief:
Protocol Section:
NCT00672932